--Vertex Pharmaceuticals Due off Trading Halt at 4:30 pm ET
4:07PM ET 10/21/2019 MT NewswiresPrice: 183.98, Change: +7.75, Percent Change: +4.40 ...
Quotes Snapshot > VRTX
Vertex Pharmaceuticals Inc VRTX:NASDAQ
Next Earnings date is expected on
10/23/2019
Last Price$183.53NASDAQ Previous Close - Last Trade as of 2:59PM ET 10/21/19
Today's Change+7.30(4.14%)
Bid (Size)$184.90 (1)
Ask (Size)$190.70 (1)
Day Low / High$174.82 - 184.81
Volume250.00
Read more news Recent News
Vertex Pharmaceuticals' Cystic Fibrosis Treatment Gets FDA Approval; Shares Rally 4% Before Halt
3:20PM ET 10/21/2019 MT NewswiresShares of Vertex Pharmaceuticals (VRTX) have been halted, last up more than 4%. The FDA approved the company's Trikafta as a triple combination treatment...
Vertex Pharmaceuticals Says Cystic Fibrosis Drugs Symdeko, Orkambi Now Reimbursed in Australia
7:22AM ET 10/21/2019 MT NewswiresBiopharmaceutical company Vertex Pharmaceuticals (VRTX) said Sunday that its Symdeko and Orkambi cystic fibrosis drugs are now reimbursable in Australia. ...
Vertex Gets Positive CHMP Opinion for Expanded Label for Cystic Fibrosis Drug
11:56AM ET 10/18/2019 MT NewswiresVertex Pharmaceuticals (VRTX) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval...
View all Commentary and Analysis
Crispr Therapeutics: At The Top Of My Shopping List
11:53AM ET 10/21/2019 Seeking AlphaSpotlight On Microsoft, Tesla And Xilinx (Stocks To Watch Podcast)
7:30AM ET 9/29/2019 Seeking AlphaStocks To Watch: Spotlight On Microsoft, Tesla And Xilinx
8:41AM ET 9/28/2019 Seeking AlphaVertex Makes Substantial Strides In Diversifying Its Pipeline
4:48PM ET 9/11/2019 Seeking AlphaCompany Profile
Business DescriptionVertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA. View company web site for more details
| Address | 50 Northern Avenue Boston, Massachusetts 02210 |
| Phone | +1.617.341.6100 |
| Number of Employees | 2,500 |
| Recent SEC Filing | 10/21/2019 4 |
| Chairman, President & Chief Executive Officer | Jeffrey M. Leiden |
| Chief Financial Officer & Executive Vice President | Charles F. Wagner |
| Chief Scientific Officer & EVP-Global Research | David Matthew Altshuler |
| Chief Medical Officer & Executive Vice President | Reshma Kewalramani |
Company Highlights
| Price Open | $177.23 |
| Previous Close | $183.53 |
| 52 Week Range | $151.80 - 195.81 |
| Market Capitalization | $47.2 B |
| Shares Outstanding | 257.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 10/23/2019 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | 20.66 |
| Earnings per Share | $8.44 |
| Beta vs. S&P 500 | N/A |
| Revenue | $3.0 B |
| Net Profit Margin | 64.55% |
| Return on Equity | 51.71% |
Analyst Ratings as of 10/16/2019
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |